Research map: Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice

Back to the article

Papers in this map

  1. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate · Kevin J. Hamblett · 2004 · 1253 citations · Cited by this paper
  2. From Pharmacodynamic Biomarker to Evaluating Treatment Response: Biomarkers in Primary Mitochondrial Diseases · 2026 · Related
  3. Antibody-drug conjugates: recent advances in conjugation and linker chemistries · Kyoji Tsuchikama · 2016 · 794 citations · Cited by this paper
  4. Deep‐Learning: An Emerging Tool to Support Model‐Informed Drug Development · 2026 · Related
  5. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index · Robert P. Lyon · 2015 · 559 citations · Cited by this paper
  6. CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing · 2026 · Related
  7. The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs · Derry C. Roopenian · 2003 · 460 citations · Cited by this paper
  8. A Generative AI Framework for Pharmacokinetic Clinical Study Report Authoring · 2026 · Related
  9. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease · Stefka B. Petkova · 2006 · 315 citations · Cited by this paper
  10. Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer · 2026 · Related
  11. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data · Rong Deng · 2011 · 287 citations · Cited by this paper
  12. Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA / EMA · 2026 · Related
  13. Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals · Ruili Wang · 2025 · 279 citations · Cited by this paper
  14. Evaluation of a Novel Peptide‐Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection · 2026 · Related
  15. Distribution of FcRn Across Species and Tissues · Sari Latvala · 2017 · 183 citations · Cited by this paper
  16. Drug Interactions of Vebreltinib, a Novel Type I c‐Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants · 2026 · Related
  17. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates · Amrita V. Kamath · 2014 · 117 citations · Cited by this paper
  18. Anti‐ PEG Antibodies From mRNA COVID ‐19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels · 2026 · Related
  19. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies · Lindsay B. Avery · 2016 · 115 citations · Cited by this paper
  20. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach · Alison M. Betts · 2018 · 114 citations · Cited by this paper
  21. Characterization and screening of IgG binding to the neonatal Fc receptor · Tobias Neuber · 2014 · 109 citations · Cited by this paper
  22. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited · Weirong Wang · 2010 · 105 citations · Cited by this paper
  23. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates · Dan Lu · 2014 · 88 citations · Cited by this paper
  24. Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data · Masataka Oitate · 2011 · 81 citations · Cited by this paper
  25. Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering · Sanghwan Ko · 2021 · 67 citations · Cited by this paper
  26. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors · Ophelia Q. P. Yin · 2020 · 65 citations · Cited by this paper
  27. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors · Yasuaki Anami · 2022 · 52 citations · Cited by this paper
  28. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma · May Garrett · 2019 · 41 citations · Cited by this paper
  29. Antibody–Drug Conjugates—Evolution and Perspectives · Adriana Aurelia Chiş · 2024 · 38 citations · Cited by this paper
  30. An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics · David W. Meyer · 2020 · 35 citations · Cited by this paper
  31. Strategic and Chemical Advances in Antibody–Drug Conjugates · Ibrahim A. Alradwan · 2025 · 33 citations · Cited by this paper
  32. Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data · Chunze Li · 2019 · 32 citations · Cited by this paper
  33. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody · Kenta Haraya · 2014 · 30 citations · Cited by this paper
  34. Improved translation of stability for conjugated antibodies using an in vitro whole blood assay · Aimee Fourie-O’Donohue · 2020 · 25 citations · Cited by this paper
  35. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates · Peiying Zuo · 2020 · 24 citations · Cited by this paper
  36. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors · Abhishek G. Sathe · 2024 · 20 citations · Cited by this paper
  37. Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development · Lili Wen · 2025 · 18 citations · Cited by this paper
  38. Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma · Brian T. Hess · 2021 · 14 citations · Cited by this paper
  39. Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice · Kenta Haraya · 2025 · 10 citations · Cited by this paper

Source: OpenAlex (CC0)